LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
about
Targeting LKB1 in cancer - exposing and exploiting vulnerabilitiesCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Nrf2 and Notch Signaling in Lung Cancer: Near the CrossroadLKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.Liver kinase B1 inhibits the expression of inflammation-related genes postcontraction in skeletal muscle.Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 statusStress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth.
P2860
Q26801412-4A851C7D-2B0D-4C7F-8BD0-10D4D64D7A9BQ27345462-385FEDDD-5AAD-40F6-8A9F-541993FD41BEQ28066915-9C91986C-1FB9-4270-B02F-E2D9CA42ECAFQ35801173-A4CE4879-A5CE-451B-BBB4-8371CECE12F8Q36371799-51698C9B-6881-4E37-950E-F6FB0A83B6F4Q36814030-1FDAA57A-CCA1-4603-B70F-10030052BC4BQ36927481-370DFC3A-6091-4EEF-A050-A9CA774E2E7FQ36951807-3241E0AA-C7B5-4C8D-B803-C4BBB70F61CAQ37218021-D4F4B845-4FB5-45AA-B6EB-04DDE7B16035Q38708958-52BED6EC-1482-41FD-86D8-8222BF134C78Q39222626-4C949A24-6E5F-4C47-851C-9E56575159C8Q39934413-F4140A9C-D1A4-439F-AA4C-B73BE6F04559Q41708717-593B151D-3769-45B6-AC7B-9AC3530AD978Q47423597-32C5A213-4F4C-44CF-95BF-A04353E684CAQ55342073-404E5AA3-E9E7-4B76-93DF-C2C72D6DBE59
P2860
LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
LKB1 Loss induces characterist ...... n and attenuation of PI3K-AKT.
@en
type
label
LKB1 Loss induces characterist ...... n and attenuation of PI3K-AKT.
@en
prefLabel
LKB1 Loss induces characterist ...... n and attenuation of PI3K-AKT.
@en
P2093
P2860
P1476
LKB1 Loss induces characterist ...... n and attenuation of PI3K-AKT.
@en
P2093
David P Carbone
Haotian Li
Jacob M Kaufman
Joseph M Amann
Kyungho Park
Rajeswara Rao Arasada
P2860
P304
P356
10.1097/JTO.0000000000000173
P577
2014-06-01T00:00:00Z